Gliknik Inc. Raises $11.5 Million in Series C Financing —Read More

Gliknik to Receive $15 Million Milestone Payment from Pfizer Inc. Following Clinical Progress with PF-06755347, Previously Known as GL-2045 —Read More

Gliknik Announces Issuance of U.S. Patent for Use of Recombinant IVIG Mimetics —Read More

Gliknik Announces Dosing of First Patient in Ph 2 Trial Targeting Prevention of Recurrence of High-Risk Oral Cavity Cancer —Read More

Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder —Read More

Gliknik Expands Clinical Development Team with New Senior Director and Adds Board Members —Read More

Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases —Read More

Gliknik adds Incyte President & Ceo Paul A. Friedman to its Board if Directors —Read More

Gliknik Announces Interim Clinical Data From Use of Its Immunomodulator Drug Candidate in Multiple Myeloma Patients —Read More

Gliknik Raises $4.9 Million in Series B Financing Led by Baxter Ventures —Read More

Published Preclinical Data Demonstrate Ability of Gliknik’s Recombinant StradomersTM to Mimic Anti-Autoimmune Effect of IVIG —Read More

National Cancer Institute Awards Gliknik Up to $1.5 Million in SBIR Funding —Read More